We are live on
!
Find out more
DA
DCF Advisers Portfolio holdings
AUM
$566M
1-Year Est. Return
197.74%
This Fund
S&P 500
This Quarter
Est. Return
+0.03%
1 Year Est. Return
+197.74%
3 Year Est. Return
+371.51%
5 Year Est. Return
+473.27%
10 Year Est. Return
–
AUM
$184M
AUM Growth
-$5.72M
(-3%)
Cap. Flow
-$594K
Cap. Flow
% of AUM
-0.32%
Top 10 Holdings %
Top 10 Hldgs %
49.88%
Holding
105
New
16
Increased
25
Reduced
26
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$1.54M |
| 2 |
Advanced Micro Devices
AMD
|
+$1.11M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$1.08M |
| 4 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
+$773K |
| 5 |
Xencor
XNCR
|
+$712K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$2.12M |
| 2 |
argenx
ARGX
|
+$1.81M |
| 3 |
Johnson & Johnson
JNJ
|
+$761K |
| 4 |
Vir Biotechnology
VIR
|
+$642K |
| 5 |
Palo Alto Networks
PANW
|
+$639K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 33.49% |
| 2 | Healthcare | 33.26% |
| 3 | Technology | 15.1% |
| 4 | Communication Services | 6.79% |
| 5 | Consumer Discretionary | 3.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
101
CALL
Vir Biotechnology
VIR
$1.87B
| – | – |
-50,100
| Closed | -$1.23M |
|
|
102
PUT
Vir Biotechnology
VIR
$1.87B
| – | – |
-34,500
| Closed | -$846K |
|
103
CALL
Wolfspeed
WOLF
$1.28B
| – | – |
-2,000
| Closed | -$111K |
|
Similar funds
LT
CIM
B
PCM
LIM
AP
CWA
CA
DCF Advisers's Q3 2023 Portfolio in Review
As of Q3 2023, DCF Advisers held 105 positions worth $184M, down 3% from $189M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
DCF Advisers's Q3 2023 filing shows 16 new, 25 increased, 26 reduced and 9 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 13,500 shares worth $986K. The largest sale was Amgen, an estimated $2.12M.
By sector, the portfolio is most concentrated in Miscellaneous at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Technology.
- DCF Advisers's largest Q3 2023 buy was State Street SPDR S&P Biotech ETF: 13,500 shares worth $986K.
- DCF Advisers added most to iShares Russell 2000 ETF in Q3 2023, an estimated $1.54M increase.
- DCF Advisers's biggest Q3 2023 reduction was Amgen, cutting an estimated $2.12M.
- DCF Advisers fully exited Palo Alto Networks in Q3 2023, selling an estimated $639K.
- DCF Advisers's ten largest holdings make up 50% of its $184M portfolio in Q3 2023.
- DCF Advisers opened 16 new positions and closed 9 in Q3 2023.
- DCF Advisers's portfolio value fell 3% quarter-over-quarter to $184M.
Based on DCF Advisers's 13F filing for Q3 2023, filed 13 Nov 2023.